Advertisement

Topics

The Mesothelioma Applied Research Foundation Company Profile

15:57 EDT 23rd September 2018 | BioPortfolio

The Meso Foundation is the only 501(c)(3) nonprofit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively seeks philanthropic support to fund mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer-reviewed scientific research to develop life-saving treatments for this extremely aggressive cancer. To date, the Foundation has awarded over $8.7 million to research. More information is available at http://www.curemeso.org.


News Articles [1079 Associated News Articles listed on BioPortfolio]

J&J To Appeal $37M Mesothelioma Verdict, A First In Talc Trials

The mesothelioma liability case marks the first in New Jersey, the first involving a male plaintiff and the first to...    

Mouse Xenograft Model for Mesothelioma

The National Cancer Institute is seeking parties interested in collaborative research to co-develop, evaluate, or commercialize a new mouse model for monoclonal antibodies and immunoconjugates that ta...

A novel research partnership in AI to advance drug discovery, longevity and aging research

(Biogerontology Research Foundation) Biogerontology Research Foundation CSO to collaborate with Insilico Medicine and WuXi AppTec on a research study in artificial intelligence for drug discovery. The...

A novel research partnership in AI to advance drug discovery, longevity & aging research

(Biogerontology Research Foundation) Thursday, June 14, London, UK: Biogerontology Research Foundation CSO to collaborate with Insilico Medicine and WuXi AppTec on a research study in artificial intel...

Mesothelioma Successfully Curbed in Test Animals

NewsAn international team of researchers has succeeded in stopping the growth of mesothelioma in model animals by inhibiting the heparanase enzyme.

Anticancer drug nintedanib found to be effective against malignant pleural mesothelioma

Researchers have found that nintedanib shows promising effectiveness in halting the growth of human malignant pleural mesothelioma in preclinical models. The post Anticancer drug nintedanib found to ...

Talcum Powder Lawsuit Trial Concludes, Jury Awards $37M To Mesothelioma Plaintiff

NewsJohnson & Johnson and Imery's Talc America have been ordered to pay $37 million to a New Jersey man who was diagnosed with mesothelioma following years of talcum powder use.

Damon Runyon Cancer Research Foundation awards over $3.6 million to nine top clinical investigators

(Damon Runyon Cancer Research Foundation) The Damon Runyon Cancer Research Foundation named six new Damon Runyon Clinical Investigators at its spring 2018 committee review. The recipients of this pres...

PubMed Articles [1622 Associated PubMed Articles listed on BioPortfolio]

A comparison of asbestos fiber potency and elongate mineral particle (EMP) potency for mesothelioma in humans.

We analyzed the mesothelioma mortality in cohorts of workers exposed to crocidolite, amosite, and chrysotile to estimate asbestos fiber potency for mesothelioma, using the method of Hodgson and Darnto...

Mesothelioma occurrence in taconite miners; assessing the role of non-asbestiform EMP.

The purpose of this paper was to assess the role of non-asbestiform amphibole EMPs in the etiology of mesotheliomas in taconite (iron ore) miners. Increased mesothelioma rates have been described in M...

Epidemiological surveillance of mesothelioma mortality in Italy.

Malignant mesothelioma (MM) is causally linked to asbestos exposure with an estimated etiological fraction of 80% or more.

Revised Modified RECIST Criteria for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1).

Malignant pleural mesothelioma poses unique difficulties in tumor measurement and response assessment; however, robust and reproducible assessment of response is critically important in the conduct, i...

Non-Coding Transcript Heterogeneity in Mesothelioma: Insights from Asbestos-Exposed Mice.

Mesothelioma is an aggressive, rapidly fatal cancer and a better understanding of its molecular heterogeneity may help with making more efficient therapeutic strategies. Non-coding RNAs represent a la...

Clinical Trials [2961 Associated Clinical Trials listed on BioPortfolio]

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

MiST is a British Lung Foundation funded, University of Leicester Study, a multi-arm stratified therapy based clinical trial for patients with relapsed mesothelioma. The goal of MiST is t...

Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia

RATIONALE: Studying levels of mesothelin and osteopontin in samples of blood from patients with mesothelioma or atypical mesothelial hyperplasia may help doctors identify biomarkers relate...

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

For patients with malignant pleural mesothelioma that has grown despite treatment with standard chemotherapy, no treatment has yet proven beneficial. The purpose of this study is to find o...

SU5416 in Treating Patients With Malignant Mesothelioma

RATIONALE: SU5416 may stop the growth of malignant mesothelioma by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who ...

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

This research study is studying a pair of immunotherapies as a possible treatment for malignant pleural mesothelioma. The drugs involved in this study are: - Durvalumab ...

Companies [2874 Associated Companies listed on BioPortfolio]

The Mesothelioma Applied Research Foundation

The Meso Foundation is the only 501(c)(3) nonprofit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively...

Mesothelioma Applied Research Foundation

Baron & Budd, P.C. .

The national mesothelioma law firm of Baron & Budd, P.C. has a more than 30-year history of “Protecting What’s Right” for asbestos sufferers and their families. As ...

Simmons Firm

The Simmons Firm, headquartered in Alton, Ill., is one of the country’s leading asbestos and mesothelioma litigation firms. With offices in Illinois, Missouri and California,...

Simmons Browder Gianaris Angelides & Barnerd LLC

The Simmons Firm, headquartered in Alton, Ill., is one of the country’s leading asbestos and mesothelioma litigation firms. With offices in Illinois, Missouri and California,...

More Information about "The Mesothelioma Applied Research Foundation" on BioPortfolio

We have published hundreds of The Mesothelioma Applied Research Foundation news stories on BioPortfolio along with dozens of The Mesothelioma Applied Research Foundation Clinical Trials and PubMed Articles about The Mesothelioma Applied Research Foundation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Mesothelioma Applied Research Foundation Companies in our database. You can also find out about relevant The Mesothelioma Applied Research Foundation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record